Retatrutide + Cagrilintide
5mg + 5mg · Sample tested 2026-10-20
99.85%
Reported combination purity
- Report reference
- RC10-2026101978935
- Measured sample net content
- Retatrutide 5.25mg; Cagrilintide 5.18mg
99.85% reported combination purityRetatrutide 5mg + Cagrilintide 5mg in a single research vial. Supplied LCMS/HPLC report lists 99.85% combination purity for the tested sample. Research use only; not approved for human or veterinary use.
In stock · 10 available
RC10 brings Retatrutide 5mg and Cagrilintide 5mg together in a single Protides Biotech research vial, for 10mg total labeled peptide content.
Retatrutide is investigated for GIP, GLP-1 and glucagon receptor activity. Cagrilintide is an investigational amylin analog. The blend is intended for laboratory examination of these distinct signaling pathways; combined efficacy or safety is not established by its analytical report.
The supplied report RC10-2026101978935 records 99.85% combination purity, with measured sample contents of 5.25mg retatrutide and 5.18mg cagrilintide. Results relate to the tested sample, not every vial. No clinical, sterility or regulatory approval is implied.
Retatrutide research examines GIP, GLP-1 and glucagon receptor signaling; cagrilintide research examines amylin-related signaling. Combining the compounds in a vial does not demonstrate synergy, therapeutic benefit or suitability for human use.
Active research area — see references below.
Active research area — see references below.
Active research area — see references below.
| Labeled composition | Retatrutide 5mg + Cagrilintide 5mg |
|---|---|
| Total labeled content | 10mg · single vial |
| Report reference | RC10-2026101978935 |
| Sample analysis date | 2026-10-20 |
| Reported purity | 99.85% combination purity (LCMS/HPLC) |
| Measured sample content | Retatrutide 5.25mg; Cagrilintide 5.18mg |
| CAS numbers (report) | Retatrutide: 2381089-83-2; Cagrilintide: 1415456-99-3 |
| Storage | Batch-specific guidance not supplied |
| Brand | Protides Biotech |
| SKU | PT-RC10-5-5 |
Research-use reconstitution reference for RC10 · Retatrutide + Cagrilintide. For qualified research settings only. Not medical advice — consult a qualified professional and follow applicable lab, safety, and regulatory protocols.
Validated handling documentation has not been supplied for this compound; no preparation amounts are recommended.
5mg + 5mg · Sample tested 2026-10-20
99.85%
Reported combination purity
Owner-supplied analytical reports for the identified samples, not a guarantee for every vial or strength. The documents state that the issuer and partner laboratory do not hold CMA/CNAS accreditation and the reports have no legal certification validity. They do not establish regulatory approval. Reported net content is a sample measurement, not the labeled strength. These reports are not Janoshik certificates.
Feedback about shopping with Protides Biotech. These comments are not reviews of RC10 · Retatrutide + Cagrilintide or its effects.
“Can we talk about the customer service? Because honestly 10/10. I had so many questions before placing my order and they answered everything without making me feel like I was bothering them. Delivery was quick too. Definitely appreciate the professionalism.”
“I was nervous about ordering at first but the Protide team was really patient with me. They answered my questions and explained the ordering process. Everything came properly packaged and the communication was excellent. Will definitely recommend their customer service.”
Request custom vial strengths, larger quantities, or sourcing for compounds not currently in our catalog. Our team will review and respond with availability and pricing.
Start Special OrderDisclaimer: Product information is provided for research and educational purposes only. This website does not provide medical advice, diagnosis, treatment, dosage instructions, or human-use recommendations.